Rigel Pharmaceuticals (RIGL) Change in Receivables (2014 - 2026)

Rigel Pharmaceuticals' Change in Receivables history runs 12 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 2573.53% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at $8.4 million (down 40.16% YoY), while the FY2025 annual figure was $10.1 million, down 8.29% from the prior year.
• Change in Receivables was -$1.8 million for Q1 2026 at Rigel Pharmaceuticals, down from $5.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $24.8 million in Q4 2022 to a low of -$11.0 million in Q1 2023.
• Historically, Change in Receivables has averaged $2.0 million across 5 years, with a median of $1.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Change in Receivables surged 5054.89% in 2022, then tumbled 4621.55% in 2023.
• A 5-year view of Change in Receivables shows it stood at $24.8 million in 2022, then plunged by 71.75% to $7.0 million in 2023, then soared by 57.62% to $11.0 million in 2024, then slumped by 47.12% to $5.8 million in 2025, then plunged by 131.14% to -$1.8 million in 2026.
• The last three Change in Receivables figures came in at -$1.8 million (Q1 2026), $5.8 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.